Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MDH2 | P40926 | 2/20 | 0.60 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nequinate SCHEMBL29365503 | 0.91 | ALDH1A1 (0.52) | ALDH1A1HPGDSMN1; SMN2MDH2GABRA1 | |
| Nequinate SCHEMBL1509158 | 0.91 | ALDH1A1 (0.52) | ALDH1A1HPGDSMN1; SMN2MDH2GABRA1 | |
| SCHEMBL27567115 | 0.88 | ALDH1A1 (0.45) | ALDH1A1HPGDSMN1; SMN2MDH2GABRA1 | |
| SCHEMBL9425394 | 0.85 | ALDH1A1 (0.72) | ALDH1A1HPGDSMN1; SMN2MDH2LMNA | |
| SCHEMBL5161582 | 0.80 | GABRA1 (0.64) | ALDH1A1HPGDSMN1; SMN2MDH2GABRA1 | |
| SCHEMBL20272166 | 0.79 | ALDH1A1 (0.48) | ALDH1A1HPGDSMN1; SMN2GABRA1GABRB2 | |
| SCHEMBL5033245 | 0.79 | POLB (0.45) | POLB | |
| SCHEMBL5159020 | 0.77 | GABRA1 (0.62) | ALDH1A1HPGDSMN1; SMN2MDH2GABRA1 | |
| SCHEMBL16491115 | 0.77 | ALDH1A1 (0.56) | ALDH1A1HPGDSMN1; SMN2MDH2MAPT | |
| SCHEMBL17181485 | 0.76 | MDH2 (0.61) | ALDH1A1HPGDSMN1; SMN2MDH2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113979941-A | Method for purifying naphthoquine ester | 瑞孚信江苏药业股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | ALDH1A1 4803/4885HPGD 2346/4885SMN1; SMN2 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.